Assessing Laboratory Capacity for Diagnosis of Fungal Infections in France: A Multicentre survey within the SINFONI Network

Clicks: 31
ID: 313428
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #142 of 187 articles by views in medical mycology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 187 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Invasive fungal diseases are life-threatening complications, particularly in immunocompromised patients, and require rapid and accurate diagnosis to improve clinical outcomes. Although major advances in fungal diagnostics that includes antigen detection, molecular assays, and MALDI-TOF mass spectrometry, have transformed diagnostic strategies, access to these tools remains heterogeneous. In France, national data on diagnostic capacities for invasive fungal diseases have been lacking. Using the framework of the national prospective surveillance program for invasive fungal diseases (SINFONI network), we conducted a survey to assess laboratory diagnostic practices in France. A secured 116-item questionnaire was distributed to 58 participating laboratories, of which 48 responded (83%). Automated blood culture systems and MALDI-TOF mass spectrometry for yeast identification were universally available, with 40 (83%) of the 48 participating laboratories also using MALDI-TOF for mold identification. Antifungal susceptibility testing was performed on-site in 47 (98%) centres for yeasts and in 37 (77%) for molds. Antigen-based biomarkers were widely available on-site, particularly cryptococcal antigen (n=43, 90%) and Aspergillus galactomannan (n=39, 81%), whereas β-D-glucan testing was available in only 26 (54%) of the centres. PCR-based diagnostics were implemented on-site in 43 (88%) centres, most commonly for Pneumocystis jirovecii, Aspergillus spp., and Mucorales. Systematic screening for Candidozyma auris colonization in at-risk patients was performed in 30 (63%) centres, predominantly using culture-based methods (n=24). Overall, this survey provides the first national overview of diagnostic capacities for invasive fungal diseases in France, highlighting a strong laboratory mycology infrastructure while identifying remaining gaps in access to specific biomarkers, molecular assays, and mold antifungal susceptibility testing.
Reference Key
openalex_W7161112568 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Florent Morio, Alexandre Alanio, Karine Boukris-Sitbon, Dea Garcia-Hermoso, Éric Dannaoui, Laurence Millon, O Lortholary, Thomas Obadia, Timothée Boyer-Chammard, Taïeb Chouaki, Marc Pihet, Joséphine Dorin, Anne-Pauline Bellanger, Sophie Brun, Maxime Lefranc, Iona Chateau, Julie Bonhomme, Maxime Moniot, Françoise Botterel, Louise Basmaciyan, Frédéric Dalle, Cécile Garnaud, Fakhri Jeddi, Marwan Haboub, Laure Kamus, C. Chassagne, Séverine Loridant, Marjorie Cornu, Marie-Fleur Durieux, Nicole Desbois-Nogard, Grégoire Pasquier, Claire Cottrel, Olivier Moquet, Lilia Hasseine, Milène Sasso, Laura Courtellemont, Christine Bonnal, Célia Rouges, Arnaud Fekkar, Maud Gits‐Muselli, Yaye Senghor, Juliette Guitard, Estelle Cateau, A Huguenin, Hélène Guegan, Maria Stoica, Céline Tournus, Caroline Mahinc, Valérie Letscher-Bru, Lucie Limousin, Emilie Guémas, Gabrielle Roosen, Guillaume Desoubeaux, Vincent Thomas, Marie-Liesse Pacreau, Élisabeth Chachaty, Fanny Lanternier, Marie Desnos-Ollivier
Are you one of these authors? Claim your profile
Journal medical mycology
Year 2026
DOI
10.1093/mmy/myag050
URL
https://doi.org/10.1093/mmy/myag050
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.